Loading data for BRTX — first visit, this takes a few seconds.

알림

BioRestorative Therapies ... (BRTX)

NasdaqCM: BRTX · 실시간 가격 · USD

0.22

+0.00 (0.00%)

종가 기준: Aug 21, 2026, 8:00 PM

0.22

+2.00%

애프터마켓: 7:50 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.00% (1D)

데이터 없음

매수호가	0.16
시가총액	5.49M
매출 (ttm)	357.87K
순이익 (ttm)	-11.06M
	0.74
	-1.06
	n/a
	-0.41
P/B (ttm)	1.81
P/S (ttm)	15.33
실적 발표일	n/a

매도호가	0.28
거래량	75,803
평균 거래량 (20일)	9,839,590
시가	0.22
전일 종가	0.22
일중 범위	0.21 - 0.22
52주 범위	0.16 - 1.89
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

BRTX 소개

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for th...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 5, 2012

직원 수 13

상장 거래소 NasdaqCM

티커 BRTX

웹사이트 https://www.biorestorative.com

전체 기업 정보

재무 실적

2025년 BioRestorative Therapies의 매출은 359.7K로, 전년 401K 대비 -10.3% 감소했습니다. 순이익은 -14.24M로, 58.61% 증가했습니다.

재무제표

어닝 서프라이즈

BioRestorative Therapies가 May 14, 2026에 분기 실적을 발표했습니다:

매출 $23.17K 예상치 하회 $0, 및 -7.32% 전년 대비 감소.
EPS -0.12 예상치 상회 0.08, 및 81.25% 전년 대비 성장.

뉴스

4일 전 · Zacks

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -83.33% and +6.72%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · Zacks

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock...

2개월 전 · MT Newswires

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the

3개월 전 · Zacks

What Makes Biorestorative Therapies (BRTX) a New Buy Stock

Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 페이지 중 1